86 related articles for article (PubMed ID: 27594296)
1. Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents.
Inagaki Y; Matsumoto Y; Tang W; Sekimizu K
Drug Discov Ther; 2016; 10(4):195-200. PubMed ID: 27594296
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo anticancer activity evaluation of ursolic acid derivatives.
Shao JW; Dai YC; Xue JP; Wang JC; Lin FP; Guo YH
Eur J Med Chem; 2011 Jul; 46(7):2652-61. PubMed ID: 21514015
[TBL] [Abstract][Full Text] [Related]
4. NC381, a novel anticancer agent, arrests the cell cycle in G0-G1 and inhibits lung tumor cell growth in vitro and in vivo.
Cao MY; Lee Y; Feng NP; Al-Qawasmeh RA; Viau S; Gu XP; Lau L; Jin H; Wang M; Vassilakos A; Wright JA; Young AH
J Pharmacol Exp Ther; 2004 Feb; 308(2):538-46. PubMed ID: 14610220
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
Doroshenko P; Sabanov V; Doroshenko N
J Cell Physiol; 2001 Apr; 187(1):65-72. PubMed ID: 11241350
[TBL] [Abstract][Full Text] [Related]
7. The hollow fiber assay: continued characterization with novel approaches.
Hall LA; Krauthauser CM; Wexler RS; Hollingshead MG; Slee AM; Kerr JS
Anticancer Res; 2000; 20(2A):903-11. PubMed ID: 10810375
[TBL] [Abstract][Full Text] [Related]
8. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.
Fedier A; Ruefenacht UB; Schwarz VA; Haller U; Fink D
Br J Cancer; 2002 Oct; 87(9):1027-33. PubMed ID: 12434296
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts.
Pinski J; Parikh A; Bova GS; Isaacs JT
Cancer Res; 2001 Sep; 61(17):6372-6. PubMed ID: 11522628
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
Li C; Qiu Y; Li X; Liu N; Yao Z
Bioorg Med Chem Lett; 2014 Feb; 24(3):855-9. PubMed ID: 24405702
[TBL] [Abstract][Full Text] [Related]
13. Screening of five specific cell cycle inhibitors using a T cell lymphoma cell line synchrony/release assay.
Yerly-Motta V; Pavy JJ; Hervé P
Biotech Histochem; 1999 May; 74(3):119-28. PubMed ID: 10416784
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127.
Ferlini C; Distefano M; Pierelli L; Bonanno G; Riva A; Bombardelli E; Ojima I; Mancuso S; Scambia G
Oncol Res; 1999; 11(10):471-8. PubMed ID: 10850888
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).
Heffeter P; Jakupec MA; Körner W; Wild S; von Keyserlingk NG; Elbling L; Zorbas H; Korynevska A; Knasmüller S; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2006 Feb; 71(4):426-40. PubMed ID: 16343446
[TBL] [Abstract][Full Text] [Related]
17. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
18. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
Sutter AP; Maaser K; Grabowski P; Bradacs G; Vormbrock K; Höpfner M; Krahn A; Heine B; Stein H; Somasundaram R; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Nov; 41(5):799-807. PubMed ID: 15519653
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
